mynth
← DATABASE
11/2020MajorityLBO

Novalpina Capital takes majority stake in Laboratoire X.O

FRANCE Life Sciences / Pharma & Biotech / Generics / Labs REV €25–50M

Context

Novalpina Capital made its first French investment by acquiring a controlling stake in Laboratoire X.O. The deal values the company at over EUR300M, supported by a unitranche debt facility from Ares Management. Novalpina has also reserved EUR100M for future acquisitions. The objective is to triple revenue within five years by acquiring more drug portfolios and expanding the group's international footprint beyond France and Francophone Africa.

Laboratoire X.O, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2015, Laboratoire X.O is a specialty pharmaceutical company focused on acquiring and revitalizing mature drug brands (Legacy Brands) from "Big Pharma." It operates an asset-light model, outsourcing production while managing 21 Market Authorizations (MA). Its portfolio includes prescription drugs and a growing Over-The-Counter (OTC) division, with key brands like Prexidine (mouthwash).

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2019
€25–50M
[members only]
[members only]
2018
€25–50M
[members only]
[members only]

Other operations with Laboratoire X.O

Other operations with Laboratoire X.O
DateAcquirerTargetCountrySector
10/2022STANLEY CAPITAL PARTNERSLABORATOIRE X.OFRANCEGenerics / Labs

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
01/2021ARDIAN / BNP PARIBAS DEVELOPPEMENTPROTEORFRANCEImplants & Prosthetics
01/2021MONTAGU PRIVATE EQUITYIMV TECHNOLOGIESFRANCER&D Biotech
10/2020SULZERHASELMEIERSWITZERLANDMedical Consumables
10/2020ARDIANH2 PHARMAFRANCECDMO
09/2020NESTLEIM HEALTHSCIENCEUNITED STATESNutrition & Dietary Supplements
09/2020PATRICIA INDUSTRIESADVANCED INSTRUMENTSUNITED STATESDiagnostic Equipment
09/2020EQT PARTNERSSCHÜLKEGERMANYMedical Consumables
09/2020PERMIRANEURAXPHARMGERMANYGenerics / Labs
06/2020AVISTA CAPITAL PARTNERSVISION HEALTHCAREBELGIUMNutrition & Dietary Supplements
04/2020ROYAL DSMGLYCOMDENMARKNutrition & Dietary Supplements

REFERENCES

Revenue range: REV €25–50M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Laboratoire X.O by Novalpina Capital are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Laboratoire X.O, a French company specialised in Pharma & Biotech, by Novalpina Capital in 2020, structured as a leveraged buyout (LBO). Ownership has since evolved, leading to a subsequent transaction with Stanley Capital Partners in October 2022 (see the dedicated deal page for details).

What was Laboratoire X.O’s revenue at the time of the deal?

At the time of the transaction, Laboratoire X.O’s annual revenue was estimated within the €25–50M range (FY 2019). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.